293 related articles for article (PubMed ID: 9952368)
1. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
Bostic JR; Brown KE; Young NS; Koenig S
J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
[TBL] [Abstract][Full Text] [Related]
2. B cell memory is directed toward conformational epitopes of parvovirus B19 capsid proteins and the unique region of VP1.
Corcoran A; Mahon BP; Doyle S
J Infect Dis; 2004 May; 189(10):1873-80. PubMed ID: 15122524
[TBL] [Abstract][Full Text] [Related]
3. An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell lines.
Caillet-Fauquet P; Di Giambattista M; Draps ML; Hougardy V; de Launoit Y; Laub R
Transfusion; 2004 Sep; 44(9):1340-3. PubMed ID: 15318858
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated opsonization of red blood cells in parvovirus B19 infection.
Chehadeh W; Halim MA; Al-Nakib W
Virology; 2009 Jul; 390(1):56-63. PubMed ID: 19450862
[TBL] [Abstract][Full Text] [Related]
5. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
Beersma MF; Claas EC; Sopaheluakan T; Kroes AC
J Clin Virol; 2005 Sep; 34(1):71-5. PubMed ID: 15985386
[TBL] [Abstract][Full Text] [Related]
6. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
7. Human parvovirus B19 infection during pregnancy--value of modern molecular and serological diagnostics.
Enders M; Schalasta G; Baisch C; Weidner A; Pukkila L; Kaikkonen L; Lankinen H; Hedman L; Söderlund-Venermo M; Hedman K
J Clin Virol; 2006 Apr; 35(4):400-6. PubMed ID: 16332455
[TBL] [Abstract][Full Text] [Related]
8. Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection.
Kerr JR; Coyle PV; DeLeys RJ; Patterson CC
J Med Virol; 1996 Jan; 48(1):68-75. PubMed ID: 8825713
[TBL] [Abstract][Full Text] [Related]
9. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
[TBL] [Abstract][Full Text] [Related]
10. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
[TBL] [Abstract][Full Text] [Related]
11. Immune response to B19 parvovirus and an antibody defect in persistent viral infection.
Kurtzman GJ; Cohen BJ; Field AM; Oseas R; Blaese RM; Young NS
J Clin Invest; 1989 Oct; 84(4):1114-23. PubMed ID: 2551923
[TBL] [Abstract][Full Text] [Related]
12. Development of an improved method of detection of infectious parvovirus B19.
Wong S; Brown KE
J Clin Virol; 2006 Apr; 35(4):407-13. PubMed ID: 16455300
[TBL] [Abstract][Full Text] [Related]
13. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen.
Heegaard ED; Rasksen CJ; Christensen J
J Med Virol; 2002 Jul; 67(3):375-83. PubMed ID: 12116031
[TBL] [Abstract][Full Text] [Related]
14. Antibody responses in parvovirus B19 infected patients.
Modrow S; Dorsch S
Pathol Biol (Paris); 2002 Jun; 50(5):326-31. PubMed ID: 12116851
[TBL] [Abstract][Full Text] [Related]
15. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection.
Pfrepper KI; Enders M; Motz M
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):362-5. PubMed ID: 16316402
[TBL] [Abstract][Full Text] [Related]
16. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
Franssila R; Hedman K
Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
[TBL] [Abstract][Full Text] [Related]
17. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay.
Manaresi E; Gallinella G; Zerbini M; Venturoli S; Gentilomi G; Musiani M
J Med Virol; 1999 Feb; 57(2):174-8. PubMed ID: 9892404
[TBL] [Abstract][Full Text] [Related]
18. Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood.
Lehmann HW; Knöll A; Küster RM; Modrow S
Arthritis Rheum; 2003 Jun; 48(6):1631-8. PubMed ID: 12794831
[TBL] [Abstract][Full Text] [Related]
19. The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production.
Tzang BS; Tsay GJ; Lee YJ; Li C; Sun YS; Hsu TC
Clin Chim Acta; 2007 Mar; 378(1-2):59-65. PubMed ID: 17169353
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
Ballou WR; Reed JL; Noble W; Young NS; Koenig S
J Infect Dis; 2003 Feb; 187(4):675-8. PubMed ID: 12599085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]